Skip to main content
Close

Lung

Protocols

Non-Small Cell Lung Cancer (Adjuvant)

LUAJNP

Adjuvant CISplatin and vinorelbine following resection of non-small cell lung cancer   


LUAJPC

Adjuvant CARBOplatin and PACLitaxel following  
resection of stage I, II and IIIA non-small cell lung cancer

Non-Small Cell Lung Cancer (Metastatic)

LUAVAFAT

First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Afatinib    


ULUAVCRIZ

Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib    


ULUAVCRIZF

First-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Crizotinib    


LUAVDC

First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with CISplatin and DOCEtaxel    


LUAVDOC

Second-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with DOCEtaxel    


LUAVERL

Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Erlotinib   


LUAVGEFF

First-Line Treatment of Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Gefitinib    


LUAVMTNE

Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) with Erlotinib After First-Line Chemotherapy   


ULUAVNIV

Treatment of Advanced Non-Small Cell Lung Cancer Using Nivolumab   

LUAVNP

Treatment for advanced non-small cell lung cancer (NSCLC) with CISplatin and vinorelbine   


LUAVPC

First-Line treatment of advanced non-small cell lung cancer (NSCLC) with CARBOplatin and PACLitaxel


LUAVPEM

Second-Line Treatment Of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pemetrexed    


LUAVPG

Treatment of advanced non-small cell lung cancer (NSCLC) with platinum and gemcitabine    


ULUAVPMTN

Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pemetrexed   


LUAVPP

First-Line Treatment of Advanced Non-Small Cell Lung Cancer With Platinum and Pemetrexed   


LUAVVIN

Treatment of advanced non-small cell lung cancer (NSCLC) with vinorelbine in elderly patients    

Non-Small Cell Lung Cancer (Combined Modality Therapy)

LULACATRT

Treatment of Locally Advanced Non-Small Cell Lung Cancer using CARBOplatin and PACLitaxel with Radiation Therapy  

LULAPE2RT

Treatment of locally advanced non-small cell lung cancer using Alternative Dosing of CISplatin and etoposide with radiation therapy 


LULAPERT

Treatment of locally advanced non-small cell lung cancer using CISplatin and etoposide with radiation therapy 

Small Cell Lung Cancer (Limited Stage)

LUSCPERT

Therapy of limited stage small cell lung cancer using CISplatin and etoposide with radiation 

Small Cell Lung Cancer (Extensive Stage)

LUSCCAV

Treatment of Extensive Small Cell Lung Cancer (SCLC) with Cyclophosphamide, DOXOrubicin and vinCRIstine (CAV) 


LUSCPE

Therapy of extensive stage small cell lung cancer (SCLC) with CISplatin and etoposide


LUSCPI

Second-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Irinotecan With or Without Platinum 


LUSCPOE

Palliative therapy of extensive stage small cell lung cancer (SCLC) with oral Etoposide


LUSCTOP

Second line treatment of recurrent small cell lung cancer (SCLC) with topotecan 

Malignant Mesothelioma

LUMMPG

Treatment of malignant mesothelioma with platinum and gemcitabine


LUMMPP

Treatment of Malignant Mesothelioma with Platinum and Pemetrexed


LUMMVIN

Treatment of Malignant Mesothelioma with Vinorelbine 

Other Thoracic Malignancies

LUOTCAV

Treatment of Thymoma/Thymic Carcinoma with Cyclophosphamide, DOXOrubicin and vinCRIstine (CAV)


LUOTPAC

Treatment of Thymoma with Platinum, DOXOrubicin and Cyclophosphamide 


LUOTPE

Treatment of thymoma with CISplatin and etoposide


LUOTPERT

Treatment of thymoma using CISplatin and etoposide with radiation therapy


LUPUPE

Treatment of Cancer of Unknown Primary Involving the Thorax with CISplatin and etoposide 

Terms of use

The information contained in these documents is a statement of consensus of BC Cancer Agency professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independant medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer Agency's terms of use available at www.bccancer.bc.ca/legal.htm.

Tab Heading
Tab Heading
SOURCE: Lung ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer Agency. All Rights Reserved.

    Copyright © 2017 Provincial Health Services Authority